Vaccinations post-allogreffe de cellules souches hématopoïétiques : lesquels ? Quand ? Comment ?
Marie Thérèse Rubio(Hôpital Necker-Enfants Malades), Ibrahim Yakoub‐Agha(Inserm), Pascal Turlure(Centre Hospitalier Universitaire de Limoges), L. Magro(Centre Hospitalier Universitaire de Lille), C. Galumbrun(Hôpital de la Timone), Éric Hermet(Centre Hospitalier Universitaire de Clermont-Ferrand), Felipe Suárez(Hôpital Necker-Enfants Malades), Étienne Daguindau(Centre Hospitalier Universitaire de Besançon), Eva de Berranger(Centre Hospitalier Universitaire de Lille), A Charbonnier(Centre Hospitalier Universitaire Amiens-Picardie), Virginie Gandemer, Ghislaine Sterkers(Délégation Paris 7), Sébastien Maury(Assistance Publique – Hôpitaux de Paris), O. Reman(Hôpital Georges-Clemenceau), Jean‐Hugues Dalle(Inserm)
Cited by 9
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)
|Bone Marrow Transplantation|2015|387